HIGHLIGHTS
- who: Prajish Iyer and Lili Wang from the Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, CA, USA have published the research: Emerging Therapies in CLL in the Era of Precision Medicine, in the Journal: Cancers 2023, x of 27/02/2023
- what: About 432 patients were enrolled, and patients were randomized to either 12 cycles of chlorambucil/obinutuzumab (Clb-Obi) or 12 cycles of Ven-Obi, and the main objective was improving PFS. In the ASCEND trial, a phase III trial focused on cytogenetic high-risk R . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.